Abstract Body

Background

Global scale-up of ART has improved HIV outcomes, with recent estimates showing that 94% of the 40.8 million people on treatment are virally suppressed (VS) (<1000 copies/mL), with similar outcomes in Kenya at 94%. Kenya, as per National HIV guidelines (2022), defines VS at <200 copies/mL. Limited evidence exists on long-term outcomes after high viral load (HVL) (>=200 copies/mL) episodes. This evaluation examines predictors of sustained viral suppression among People Living with HIV (PLHIV) on ART, following a HVL episode.

Methods

A retrospective analysis was conducted among PLHIV on ART in 15 facilities in Makueni County, Kenya with viral load (VL) >200 copies/mL, between October 2022 and September 2024, with >2 subsequent VL results. Data were extracted from the Kenya electronic medical records system. Median (interquartile range (IQR)), frequency, and proportions were used to describe characteristics of the PLHIV. The adjusted modified Poisson regression with robust estimators was used to assess associations with sustained viral suppression (SVS), defined as two consecutive repeat VS results. 

Results

 A total of 906 PLHIV had viremia (>200 copies/mL) in the period, with 544 meeting eligibility of ≥2 follow-up VL. Median age was 39 years (IQR: 22–50), 359 (66%) were female, 510 (94%) were on a dolutegravir-based regimen, and median time on ART was 6.8 years (IQR 2.6 – 10.8) and 324(60%) had been on ART for >5 years. At baseline, 279 (51%) had VL of 200 – 999 copies and 265 (49%) >1000 copies/ml. Following the two consecutive repeat VLs, 337(62%) achieved SVS, 56(10%) experienced VS followed by HVL and 64(12%) had two consecutive HVL. Median time to repeat VL was 5.8 months (IQR: 4.7 – 7.9), with 259(49%) conducted >6 months. In adjusted analysis, predictors of SVS included older age (adjusted Risk Ratios (aRR) 1.01, 95% CI: 1.00–1.01), longer ART duration (1–5 vs <1 year; aRR 1.3, 95% CI: 1.1–1.5), delayed repeat VL testing (3–6 vs <3 months; aRR 1.8, 95% CI: 1.1–2.7), female sex (aRR 1.3, 95% CI: 1.2–1.5), and lower-level viremia (200–999 vs >1,000; aRR 1.2, 95% CI: 1.1–1.4).

Conclusions

Age, time to repeat VL, duration on ART, and VL category were significantly associated with SVS. Understanding viremic PLHIV is essential in achieving SVS following an episode of HVL. Strengthening existing strategies and developing novel viremia management interventions could be critical towards ART suppression goals.